<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02387853</url>
  </required_header>
  <id_info>
    <org_study_id>LP0053-1108</org_study_id>
    <nct_id>NCT02387853</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis</brief_title>
  <official_title>Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to &lt; 17 Years) With Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An international, multi-centre, prospective, open-label, non-controlled, single-group, 4-week
      trial in adolescent subjects with plaque psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">May 1, 2018</completion_date>
  <primary_completion_date type="Actual">April 3, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>up to week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjects with serum cortisol concentration of ≤18 mcg/dl at 30 minutes after ACTH-challenge at Week 4</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in albumin-corrected serum calcium from baseline (SV2) to Week 4</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in calcium excretion from baseline (SV2) to Week 4 in 24-hour urine</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in calcium:creatinine ratio from baseline (SV2) to Week 4 in 24-hour urine</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in calcium:creatinine ratio from baseline (SV2) in spot urine</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects with 'treatment success' according to Physician's Global Assessment(PGA) on Body</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects with 'treatment success' according to Physician's Global Assessment(PGA) on Scalp</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>LEO 90100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 90100</intervention_name>
    <arm_group_label>LEO 90100</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (all subjects)

          -  Psoriasis vulgaris on trunk and/or limbs affecting at least 2% BSA.

          -  Psoriasis vulgaris on the scalp affecting at least 10% of total scalp area.

          -  A total psoriatic involvement on trunk, limbs and scalp not exceeding 30% BSA.

          -  PGA score of at least mild on trunk and/or limbs at SV1, SV2 and V1.

          -  PGA score of at least mild on scalp at SV1, SV2 and V1.

          -  A serum albumin-corrected calcium below the upper reference limit at SV2.

        Inclusion Criteria (for subjects performing HPA axis assessment)

          -  Psoriasis vulgaris on trunk and/or limbs affecting at least 10% BSA.

          -  Psoriasis vulgaris on the scalp affecting at least 20% of total scalp area.

          -  PGA score of at least moderate on trunk and limbs at SV1, SV2 and V1.

          -  PGA score of at least moderate on scalp at SV1, SV2 and V1.

          -  Normal HPA axis function at SV2 (serum cortisol concentration above 5 mcg/dl before
             ACTH challenge and serum cortisol concentration above 18 mcg/dl 30 minutes after ACTH
             challenge).

        Exclusion Criteria (all subjects):

          -  A history of hypersensitivity to any component of LEO 90100.

          -  Systemic treatment with biological therapies (marketed or not marketed), with a
             possible effect on scalp and/or body psoriasis within the following time period prior
             to V1 and during the trial:

               1. etanercept - within 4 weeks prior to V1

               2. adalimumab, infliximab - within 2 months prior to V1

               3. ustekinumab - within 4 months prior to V1

               4. experimental products - within 4 weeks/5 half-lives (whichever is longer) prior
                  to V1

          -  Systemic treatment with therapies other than biologicals, with a possible effect on
             scalp and/or body psoriasis (e.g. methotrexate, retinoids, immunosuppressants) within
             4 weeks prior to V1 or during the trial.

          -  PUVA therapy within 4 weeks prior to V1.

          -  UVB therapy within 2 weeks prior to V1 or during the trial.

        Exclusion Criteria (for subjects performing HPA axis assessment):

          -  A history of serious allergy, allergic asthma or serious allergic skin rash.

          -  Known or suspected hypersensitivity to any component of CORTROSYN® (including
             ACTH/cosyntropin/tetracosactide)

          -  Systemic treatment with corticosteroids (including inhaled and nasal steroids) within
             12 weeks prior to SV2 or during the trial.

          -  Oestrogen therapy (including contraceptives) or any other medication known to affect
             cortisol levels or HPA axis integrity within 4 weeks prior to SV2 or during the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M Seyger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC St Radboud</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Bowen</last_name>
    <phone>+45 4494 5888</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital at Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J Teng, MD</last_name>
    </contact>
    <investigator>
      <last_name>J Teng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Redwood Family Dermatology</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403-2805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J Sugarman, MD</last_name>
    </contact>
    <investigator>
      <last_name>J Sugarman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamzavi Dermatology</name>
      <address>
        <city>Fort Gratiot</city>
        <state>Michigan</state>
        <zip>48059-3526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F Hamzavi, MD</last_name>
    </contact>
    <investigator>
      <last_name>F Hamzavi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenwich Village Dermatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R Buka, MD</last_name>
    </contact>
    <investigator>
      <last_name>R Buka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skin Speciality Dermatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F Cook-Bolden, MD</last_name>
    </contact>
    <investigator>
      <last_name>F Cook-Bolden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology Treatment and Research Center PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230-5808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W Abramovits, MD</last_name>
    </contact>
    <investigator>
      <last_name>W Abramovits</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC St Radboud</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Seyger, MD</last_name>
    </contact>
    <investigator>
      <last_name>M Seyger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MULTIKLINIKA SALUTE Sp zo.o.</name>
      <address>
        <city>Katowice</city>
        <zip>40-123</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edyta Gebska, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Boli Infectioase si Tropicale</name>
      <address>
        <city>Bucharest</city>
        <zip>030303</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxana Georgescu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Roxana Georgescu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2015</study_first_submitted>
  <study_first_submitted_qc>March 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2015</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

